Conformational selection, dynamic restriction and the hydrophobic effect coupled to stabilization of the BIR3 domain of the human X-linked inhibitor of apoptosis protein by the tetrapeptide AVPI

Biophysical Chemistry

Volumn 152, Issue 1-3, 2010, Pages 99-108

  de Souza, Theo Luiz Ferraz ^a   Sanches, Daniel ^a   Gonçalves, Rafael Braga ^a   da RochaPita, Samuel Silva ^a   Pascutti, Pedro Geraldo ^a   Bianconi, M Lucia ^a   de Almeida, Fabio Ceneviva Lacerda ^a   Silva, Jerson L ^a   de Oliveira, Andréa Cheble ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; Calorimetry; Protein stability; Spectroscopy; Thermodynamics; XIAP BIR3 AVPI interaction

Indexed keywords

BIR3 PROTEIN; TETRAPEPTIDE; TETRAPEPTIDE AVPI; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CONFORMATIONAL TRANSITION; DYNAMICS; ENTROPY; HUMAN; HYDROPHOBICITY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STABILITY; THERMODYNAMICS;

EID: 78149238395     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2010.08.005     Document Type: Article

References (73)

1. Steller H. Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449.
2. Salvesen G.S., Duckett C.S. IAPs proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
3. JacobsonWeil M., Raff M. Programmed cell death in animal development. Cell 1997, 88:347-354.
4. Deveraux Q.L., Reed J.C. IAP family proteins-supressors of apoptosis. Genes Dev. 1999, 13:239-252.
5. Fesik S.W. Insights into programmed cell death through structural biology. Cell 2000, 103:273-282.
6. Takahashi R., Deveraux Q., Tamm I., Welsh K., Assa-Munt N., Salvesen G.S., Reed J.C. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 1998, 273:7787-7790.
7. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001, 104:791-800.
8. Chai J., Shiozaki E., Srinivasula S.M., Wu Q., Datta P., Alnemri E.S., Shi Y. Structural basis of caspase-7 inhibition by XIAP. Cell 2001, 104:769-780.
9. Huang Y., Park Y.C., Rich R.L., Segal D., Myszka D.G., Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001, 104:781-790.
10. Deveraux Q.L., Stennicke E.L.H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999, 18:5242-5251.
11. Sun C., Cai M., Meadows R.P., Xu N., Gunasekera A.H., Herrmann J., Wu J.C., Fesik S.W. NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 2000, 275:33777-33781.
12. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki J.C., Lee R.A., Robbins P.D., Fernandes-Alnemri T., Shi Y., Alnemri E.S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001, 410:112-116.
13. Chai J., Du C., Wu J.W., Kyin S., Wang X., Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000, 406:855-862.
14. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., Herrmann J., Wu J.C., Fesik S.W. Structural basis of binding of Smac/DIALBLO to the XIAP BIR3 domain. Nature 2000, 408:1004-1008.
15. Wu G., Chai J., Suber T.L., Wu J., Du C., Wang X., Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000, 408:1008-1012.
16. Srinivasula S.M., Datta P., Fan X.J., Fernandes-Alnemri T., Huang Z., Alnemri E.S. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J. Biol. Chem. 2000, 275:36152-36157.
17. Wu J.W., Cocina A.E., Chai J., Hay B.A., Shi Y. Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides. Mol. Cell 2001, 8:95-104.
18. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
19. Tamm L., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., Scudiero D.A., Tudor G., Qui Y.H., Monks A., Andreeff M., Reed J.C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 2000, 6:1796-1803.
20. Vucic D., Stennicke H.R., Pisabarro M.T., Salvesen G.S., Dixit V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 2000, 10:1359-1366.
21. Mizutani Y., Nakanishi H., Li Y.N., Matsubara H., Yamamoto K., Sato N., Nakamura T., Mikami K., Takaha N., Ukimura O., Kawauchi A., Nonomura N., Bonavida B., Miki T. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. 2007, 30(4):919-925.
22. Holcik M., Yeh C., Korneluk R.G., Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000, 19:4174-4177.
23. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000, 60:5659-5666.
24. Ng C.P., Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 2002, 1:1051-1058.
25. Hu Y., Cherton-Horvat G., Dragowska V., Baird S., Korneluk R.G., Durkin J.P., Mayer L.D., LaCasse E.C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cells in vitro and in vivo. Clin. Cancer Res. 2003, 9:2826-2836.
26. Nikolovska-Coleska Z., Wang R., Fang X., Pan H., Tomita Y., Li P., Roller P.P., Krajewski K., Saito N.G., Stuckey J.A., Wang S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 2004, 332:261-273.
27. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 2004, 47:4417-4426.
28. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
29. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 2002, 277:44236-44243.
30. Yang L., Mashima T., Sato S., Mochizuki M., Sakamoto H., Yamori T., Oh-hara T., Tsuruo T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003, 63:831-837.
31. Sun H., Stuckey J.A., Nikolovska-coleska Z., Qin D., Meagher J.L., Qiu S., Lu J., Yang C., Saito N.G., Wang S. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J. Med. Chem. 2008, 51:7169-7180.
32. Gonçalves R.B., Sanches D., Souza T.L., Silva J.L., Oliveira A.C. The proapoptotic protein Smac/DIABLO dimer has the highest stability as measured by pressure and urea denaturation. Biochemistry 2008, 47(12):3832-3841.
33. Lima S.M., Vaz A.C., Souza T.L., Peabody D.S., Silva J.L., Oliveira A.C. Dissecting the role of protein-protein and protein-nucleic acid interactions in MS2 bacteriophage stability. FEBS J. 2006, 273(7):1463-1475.
34. Freire E. The thermodynamic linkage between protein structure, stability, and function. Methods Mol. Biol. 2001, 168:37-68.
35. Olsson T.S.G., Williams M.A., Pitt W.R., Ladbury J.E. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J. Mol. Biol. 2008, 384:1002-1017.
36. Ribeiro E.A., Ramos C.H. Circular permutation and deletion studies of myoglobin indicate that the correct position of its N-terminus is required for native stability and solubility but not for native-like heme binding and folding. Biochemistry 2005, 44:4699-4709.
37. Cherny I., Overgaard M., Borch J., Bram Y., Gerdes K., Gazit E. Structural and thermodynamic characterization of the Escherichia coli RelBE toxin-antitoxin system: indication for a functional role of differential stability. Biochemistry 2007, 46(43):12152-12163.
38. Pace N.C. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol. 1986, 131:266-280.
39. Weber G. Protein interactions 1992, Chapman and Hall, New York.
40. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6(3):277-293.
41. Johnson B.A., Blevins R.A. NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 1994, 4:603-614.
42. Hess L.B., Kutzner C., van der Spoel D., Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008, 4(2):435-447.
43. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., Hermans J. Interaction model for water in relation to protein hydration. Intermolecular Forces 1981, D. Reidel Publishing Company, Dordrecht, The Netherlands. B. Pullman (Ed.).
44. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., Nola A.D., Haak J.R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81:3684-3690.
45. Hess L.B., Bekker H., Berendsen H.J.C., Fraaije J.G. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 1997, 18:1463-1472.
46. van Gunsteren W.F., Billeter S.R., Eising A.A., Hünenberger P.H., Krüger P., Mark A.E., Scott W.R.P., Tironi I.G. Biomolecular Simulation: The GROMOS96 Manual and User Guide 1996, Hochschulverlag AG an der ETH Zürich, Zürich, Switzerland.
47. Leavitt S., Freire E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 2001, 11(5):560-566.
48. Cooper A. Heat capacity effects in protein folding and ligand binding: a re-evaluation of the role of water in bimolecular thermodynamics. Biophys. Chem. 2005, 115:80-97.
49. Silva J.L., Foguel D., Da Poian A.T., Prevelige P.E. The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Curr. Opin. Struct. Biol. 1996, 6:166-175.
50. Silva J.L., Foguel D., Royer C.A. Pressure provides new insights into protein folding, dynamics and structure. Trends Biochem. Sci. 2001, 26:612-618.
51. Valente A.P., Miyamoto C.A., Almeida F.C. Implications of protein conformational diversity for binding and development of new biological active compounds. Curr. Med. Chem. 2006, 13:3697-3703.
52. Blundell T.L., Sibanda B.L., Montalva R.W., Brewerton S., Chelliah V., Worth C.L., Harmer N.J., Davies O., Burke D. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Phil. Trans. R. Soc. B 2006, 361:413-423.
53. Lacasse E.C., Baird S., Korneluck R.G., Mackenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
54. Nachmias B., Ashhab Y., Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol. 2004, 14:231-243.
55. Verhagen A., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing inhibitor of apoptosis (IAP) proteins. Cell 2000, 102:43-53.
56. Weber P.C., Salemme F.R. Applications of calorimetric methods to drug discovery and the study of protein interactions. Curr. Opin. Struct. Biol. 2003, 13:115-121.
57. Lafont V., Armstrong A.A., Ohtaka H., Kiso Y., Amzel M., Freire E. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem. Biol. Drug Des. 2007, 69:413-422.
58. Whitesides G.M., Krishnamurthy V.M. Designing ligands to bind proteins. Q. Rev. Biophys. 2005, 38:385-395.
59. Celej M.S., Montich G.G., Fidelio G.D. Protein stability induced by ligand binding correlates with changes in protein flexibility. Protein Sci. 2003, 12:1496-1506.
60. Fukada H., Sturtevant J.M., Quiocho F.A. Thermodynamics of the binding of L-arabinose and of D-galactose to the L-arabinose-binding protein of Escherichia coli. J. Biol. Chem. 1983, 258(21):13193-13198.
61. Shrake A., Ross P.D. Ligand-induced biphasic protein denaturation. J. Biol. Chem. 1990, 265(9):5055-5059.
62. Shrake A., Ross P.D. Origins and consequences of ligand-induced multiphasic thermal protein denaturation. Biopolymers 1992, 32(8):925-940.
63. Pace C.N. Energetics of protein hydrogen bonds. Nat. Struct. Mol. Biol. 2009, 16(7):681-682.
64. Cordier F., Wang C., Grzesiek S., Nicholson L.K. Ligand-induced strain in hydrogen bounds of the c-Src SH3 domain detected by NMR. J. Mol. Biol. 2000, 304:497-505.
65. Stone M.J. NMR relaxation studies of the role of conformational entropy in protein stability and ligand binding. Acc. Chem. Res. 2001, 34(5):379-388.
66. Moore C.D., Wu H., Bolanos B., Bergqvist S., Brooun A., Pauly T., Nowlin D. Structural and biophysical characterization of XIAP BIR3 G30E mutant: insights in protein dynamics and application for fragment-based drug design. Chem. Biol. Drug Des. 2009, 74:212-223.
67. Sturtevant J.M. Heat capacity and entropy changes in processes involving proteins. Proc. Nat. Acad. Sci. U.S.A. 1977, 74(6):2236-2240.
68. Eftink M.R., Anusiem A.C., Biltonen R.L. Enthalpy-entropy compensation and heat capacity changes for protein-ligand interactions: general thermodynamic models and data for the binding of nucleotides to ribonuclease A. Biochemistry 1983, 22(16):3884-3896.
69. Wang C., Pawley N.H., Nicholson L.K. The role of backbone motions in ligand binding to the c-Src SH3 domain. J. Mol. Biol. 2001, 313:873-887.
70. Zidek L., Novotny M.V., Stone M.J. Increased protein backbone conformational entropy upon hydrophobic ligand binding. Nat. Struct. Biol. 1999, 6:1118-1121.
71. Lee A.L., Kinnear S.A., Wand A.J. Redistribution and loss of side chain entropy upon formation of a calmodulin-peptide complex. Nat. Struct. Biol. 2000, 7:72-77.
72. Frederick K.K., Marlow M.S., Valentine K.G., Wand A.J. Conformational entropy in molecular recognition by proteins. Nature 2007, 448:325-330.
73. Crespo A., Fernandez A. Induced disorder in protein-ligand complexes as a drug-design strategy. Mol. Pharm. 2008, 5(3):430-437.